Advancements in the Development of Anti-SARS-CoV-2 Therapeutics

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39409149

Authors

Junjie Huang

Qianqian Ma

Zhengding Su

Xiyao Cheng

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, and so far, it has occurred five noteworthy variants of concern (VOC). SARS-CoV-2 invades cells by contacting its Spike (S) protein to its receptor on the host cell, angiotensin-converting enzyme 2 (ACE2). However, the high frequency of mutations in the S protein has limited the effectiveness of existing drugs against SARS-CoV-2 variants, particularly the Omicron variant. Therefore, it is critical to develop drugs that have highly effective antiviral activity against both SARS-CoV-2 and its variants in the future. This review provides an overview of the mechanism of SARS-CoV-2 infection and the current progress on anti-SARS-CoV-2 drugs.

References

Wang R, Zhang Q, Zhang R, Aw Z, Chen P, Wong Y . SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Front Immunol. 2022; 13:854952. PMC: 9247160. DOI: 10.3389/fimmu.2022.854952. View

Butler C, Hobbs F, Gbinigie O, Rahman N, Hayward G, Richards D . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2022; 401(10373):281-293. PMC: 9779781. DOI: 10.1016/S0140-6736(22)02597-1. View

Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C . Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016; 291(17):9218-32. PMC: 4861487. DOI: 10.1074/jbc.M116.716100. View

Kuriakose J, Montezano A, Touyz R . ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clin Sci (Lond). 2021; 135(2):387-407. PMC: 7846970. DOI: 10.1042/CS20200480. View

Napolitano V, Dabrowska A, Schorpp K, Mourao A, Barreto-Duran E, Benedyk M . Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chem Biol. 2022; 29(5):774-784.e8. PMC: 8751734. DOI: 10.1016/j.chembiol.2021.11.006. View

Ortega M, Garcia-Montero C, Fraile-Martinez O, Colet P, Baizhaxynova A, Mukhtarova K . Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. J Pers Med. 2022; 12(6). PMC: 9225183. DOI: 10.3390/jpm12060995. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y . SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther. 2021; 6(1):430. PMC: 8678971. DOI: 10.1038/s41392-021-00852-5. View

10.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

11.

Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View

12.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

13.

Yang H, Wang Z, Jiang C, Zhang Y, Xu M, Zhang Y . Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study. J Med Virol. 2023; 95(7):e28947. DOI: 10.1002/jmv.28947. View

14.

Brevini T, Maes M, Webb G, John B, Fuchs C, Buescher G . FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022; 615(7950):134-142. PMC: 9977684. DOI: 10.1038/s41586-022-05594-0. View

15.

Yue C, Song W, Wang L, Jian F, Chen X, Gao F . ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023; 23(3):278-280. PMC: 9897732. DOI: 10.1016/S1473-3099(23)00010-5. View

16.

Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T . Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clin Infect Dis. 2022; 76(8):1403-1411. PMC: 10110269. DOI: 10.1093/cid/ciac933. View

17.

Shapira T, Monreal I, Dion S, Buchholz D, Imbiakha B, Olmstead A . A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022; 605(7909):340-348. PMC: 9095466. DOI: 10.1038/s41586-022-04661-w. View

18.

Yuan S, Gao X, Tang K, Cai J, Hu M, Luo P . Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell. 2022; 13(12):940-953. PMC: 8983325. DOI: 10.1007/s13238-022-00909-3. View

19.

Li K, Meyerholz D, Bartlett J, McCray Jr P . The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021; 12(4):e0097021. PMC: 8406266. DOI: 10.1128/mBio.00970-21. View

20.

Patone M, Thomas K, Hatch R, Tan P, Coupland C, Liao W . Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021; 21(11):1518-1528. PMC: 8219489. DOI: 10.1016/S1473-3099(21)00318-2. View